Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100GuruFocus · 1 day ago
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026GuruFocus · 3 days ago
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026Business Wire · 3 days ago
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical ComparisonDefense World · Oct 17, 2026
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific MeetingsBusiness Wire · Oct 15, 2026
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting PharmaFool - Investing News · Oct 10, 2026Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | $0.01 | -$0.18 | Miss |
| May 7, 2026 | -$0.00 | $0.01 | Beat |
| Mar 2, 2026 | $0.03 | $0.06 | Beat |
| Nov 6, 2025 | $0.01 | $0.00 | Miss |
| Aug 7, 2025 | -$0.03 | -$0.01 | Beat |
| May 8, 2025 | -$0.07 | -$0.06 | Beat |